Tabilautide

From Wikipedia, the free encyclopedia
Tabilautide
Names
IUPAC name
(2S,6S)-6-Amino-6-carbamoyl-2-[(4R)-4-carboxy-4-[(2R)-2-dodecanamidopropanamido]butanamido]hexanoic acid
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
UNII
  • InChI=1S/C27H49N5O8/c1-3-4-5-6-7-8-9-10-11-15-22(33)30-18(2)25(36)32-21(27(39)40)16-17-23(34)31-20(26(37)38)14-12-13-19(28)24(29)35/h18-21H,3-17,28H2,1-2H3,(H2,29,35)(H,30,33)(H,31,34)(H,32,36)(H,37,38)(H,39,40)/t18-,19-,20-,21+/m0/s1
    Key: TUNXCNXMSJZNPO-XSDIEEQYSA-N
  • CCCCCCCCCCCC(=O)N[C@H](C)C(=O)N[C@H](CCC(=O)N[C@@H](CCC[C@H](N)C(N)=O)C(O)=O)C(O)=O
Properties
C27H49N5O8
Molar mass 571.716 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Tabilautide is an immunological agent. It was studied as a potential drug for the treatment of cancer, but development for this purpose has been discontinued.[1]

References[edit]

  1. ^ "Tabilautide". Adis Insight.